Guidelines Versus Guidelines
Authors: Cait O'Sullivan, Aaron M. Tejani, Thomas Finucane
Journal: Annals of Internal Medicine (2018)

Letters18 December 2018Guidelines Versus GuidelinesCait O'Sullivan, PharmD, Aaron M. Tejani, PharmD, and Thomas Finucane, MDCait O'Sullivan, PharmDUniversity of British Columbia, Vancouver, British Columbia, Canada (C.O., A.M.T.)Search for more papers by this author, Aaron M. Tejani, PharmDUniversity of British Columbia, Vancouver, British Columbia, Canada (C.O., A.M.T.)Search for more papers by this author, and Thomas Finucane, MDJohns Hopkins Bayview Medical Center, Baltimore, Maryland (T.F.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L18-0559 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:We read Draznin and colleagues' commentary (1) with interest. Billions of dollars are spent on drugs targeting strict glycemic control in type 2 diabetes mellitus. Moderating the practice of strict glycemic control would affect the sales of these drugs and could have financial implications for several parties, including corporations that sell diabetes drugs and professional organizations that promote tight glycemic control (such as the American Diabetes Association [ADA]).Draznin and colleagues (1) firmly favor selling more drugs to persons with type 2 diabetes than does the American College of Physicians guideline (2), which advises moderation of drug ...References1. Draznin B, Nathan DM, Korytkowski MT, McDonnell ME, Golden SH, Schutta MH, et al. Guidelines versus guidelines: what's best for the patient? Ann Intern Med. 2018;169:186-7. [PMID: 29800101]. doi:10.7326/M18-0939 LinkGoogle Scholar2. Qaseem A, Wilt TJ, Kansagara D, Horwitch C, Barry MJ, Forciea MA; Clinical Guidelines Committee of the American College of Physicians. Hemoglobin A1c targets for glycemic control with pharmacologic therapy for nonpregnant adults with type 2 diabetes mellitus: a guidance statement update from the American College of Physicians. Ann Intern Med. 2018;168:569-76. [PMID: 29507945]. doi:10.7326/M17-0939 LinkGoogle Scholar3. American Diabetes Association. Our corporate sponsors. Updated 19 July 2017. Accessed at www.diabetes.org/about-us/corporate-support/our-corporate-supporters.html on 22 May 2018. Google Scholar4. ProPublica. William T. Cefalu. Dollars for Docs. 2018. Accessed at https://projects.propublica.org/docdollars/doctors/pid/670136 on 22 May 2018. Google Scholar5. Open Payments. Physician profile for William Cefalu. 2018. Accessed at https://openpaymentsdata.cms.gov/physician/670136/summary on 22 May 2018. Google Scholar Author, Article, and Disclosure InformationAffiliations: University of British Columbia, Vancouver, British Columbia, Canada (C.O., A.M.T.)Johns Hopkins Bayview Medical Center, Baltimore, Maryland (T.F.)Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L18-0559. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoGuidelines Versus Guidelines: What's Best for the Patient? Boris Draznin , David M. Nathan , Mary T. Korytkowski , Marie E. McDonnell , Sherita Hill Golden , Mark H. Schutta , and William T. Cefalu Guidelines Versus Guidelines Boris Draznin , David M. Nathan , Mary T. Korytkowski , Marie E. McDonnell , Sherita Hill Golden , Mark H. Schutta , and William T. Cefalu Metrics 18 December 2018Volume 169, Issue 12Page: 895-896KeywordsConflicts of interestDisclosureDrug delivery system preparationDrug regulationDrugsType 2 diabetes ePublished: 18 December 2018 Issue Published: 18 December 2018 Copyright & PermissionsCopyright © 2018 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...